Research Reports
- 8/9/2023
2Q23 Reported With Trial Enrollment Making Progress
- 7/11/2023
THIO-101 Part A Survival Data Reaches 12 Months
- 6/21/2023
Phase 2 THIO-101 Trial Reaches Recruitment Milestone
- 5/9/2023
1Q23 Reported As Trial Progress Continues
- 4/19/2023
Publication Details Efficacy and Mechanism In HCC Models
- 4/12/2023
THIO-101 Part A Shows Safety And Tolerability
- 3/31/2023
Clinical Progress Continues With 4Q22 Report
- 2/21/2023
Initiating Coverage With A $14 Price Target